Cardiogen vs Telmisartan
A side-by-side research comparison of Cardiogen and Telmisartan across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cardiogen | Telmisartan |
|---|---|---|
| Full name | Cardiogen (Ala-Glu-Asp-Arg Cardiac Bioregulator) | Telmisartan (ARB / Partial PPAR-gamma Agonist) |
| Category | Cardiovascular | Cardiovascular |
| Status | Research compound (peptide bioregulator) | FDA-approved drug |
| Mechanism | As a signal peptide (Ala-Glu-Asp-Arg), it is proposed to regulate gene expression in myocardial tissue, supporting cardiomyocyte function, myocardial protein synthesis, and normal cardiac tissue maintenance. | Blocks the angiotensin II type 1 (AT1) receptor to lower blood pressure and reduce vascular inflammation, while also acting as a partial PPAR-gamma agonist that improves insulin sensitivity, lipid handling, and mitochondrial biogenesis. |
| Molecular weight | ~460 Da | 514.62 Da |
| Half-life | Short (peptide) | ~24 hours |
| Bioavailability | Oral (encapsulated) or subcutaneous | ~42-58% oral |
| Typical dose | ~1-2 capsules/day or short injectable courses | 20-80 mg per day |
| Frequency | Once daily | Once daily |
| Route | Oral capsule or subcutaneous | Oral tablet |
Cardiogen reported benefits
- Cardiac/myocardial tissue support
- Cardiovascular resilience (proposed)
- Myocardial protein synthesis support
- Short course-based protocol
Telmisartan reported benefits
- Blood pressure control
- PPAR-gamma metabolic benefits
- Improved insulin sensitivity
- Vascular anti-inflammatory effects
- Cardio- and reno-protection
- 24-hour coverage
Related comparisons
Research and educational reference only. Not medical advice.